PIK3CA-related overgrowth spectrum

Gravity Branding names Novartis’ Vijoice® (alpelisib)

Retrieved on: 
Monday, August 8, 2022

SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gravity Branding, the agency behind naming blockbuster drugs including Novartis Kisqali (ribociclib), Genentechs Herceptin (trastuzumab) and Janssens Concerta (methylphenidate HCl), recently announced its success naming Vijoice (alpelisib), a Novartis drug to combat PIK3CA-Related Overgrowth Spectrum (PROS).

Key Points: 
  • SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gravity Branding, the agency behind naming blockbuster drugs including Novartis Kisqali (ribociclib), Genentechs Herceptin (trastuzumab) and Janssens Concerta (methylphenidate HCl), recently announced its success naming Vijoice (alpelisib), a Novartis drug to combat PIK3CA-Related Overgrowth Spectrum (PROS).
  • Weve enjoyed a highly collaborative, productive working relationship with the Novartis team over many years on a wide range of projects, said Edward Saenz, Managing Director, Gravity Branding.
  • For naming Vijoice, as with other initiatives, we employed our proven Brand Bullseye process, which helps teams align around a singular expression of brand value.
  • In addition to Gravitys pharmaceutical naming experience, the agency works alongside Novartis and its technology partners on branding ground-breaking digital therapeutics.

Solstice HealthCommunications’ Patient Journey Work is Published in Prestigious Journal

Retrieved on: 
Monday, May 23, 2022

Solstice, a full-service, woman-owned, communications agency is excited to announce that its patient journey project has been documented and published in the May issue of the Orphanet Journal of Rare Diseases, the portal for rare diseases and orphan drugs.

Key Points: 
  • Solstice, a full-service, woman-owned, communications agency is excited to announce that its patient journey project has been documented and published in the May issue of the Orphanet Journal of Rare Diseases, the portal for rare diseases and orphan drugs.
  • Mapping the PIK3CA-Related Overgrowth Spectrum (PROS) Patient and Caregiver Journey Using a Patient-Centered Approach explains how Solstice used its novel methodology to develop a patient engagement roadmap for PROS conditions.
  • A large pharmaceutical company selected Solstice to develop this journey, which was created in concert with patients, caregivers, and advocates as key partners.
  • A better understanding of the entire patient experience through this journey analysis method will help Pharma/Biotech develop the appropriate patient and caregiver strategies to effectively address educational and support needs.

Novartis launches "Meet The PROS" to raise awareness and support education for PIK3CA-Related Overgrowth Spectrum (PROS)

Retrieved on: 
Tuesday, August 31, 2021

Through theMeet The PROSinitiative, we aim to answer the community's call for more awareness and educational resources," said Reshema Kemps-Polanco, Head of Novartis Oncology, US.

Key Points: 
  • Through theMeet The PROSinitiative, we aim to answer the community's call for more awareness and educational resources," said Reshema Kemps-Polanco, Head of Novartis Oncology, US.
  • "I'm hopeful that these resources will help parents and families learn more, feel less alone and raise awareness about the physical and emotional impacts of these rare conditions."
  • "It's great to have additional resources, created by and for the community, to help raise awareness and education about PROS."
  • Located in East Hanover, NJ, Novartis Pharmaceuticals Corporation an affiliate of Novartis is reimagining medicine to improve and extend people's lives.

ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum

Retrieved on: 
Wednesday, October 2, 2019

ArQule, Inc. (Nasdaq: ARQL), today announced that the first patient was dosed in the registrational MOSAIC (Miransertib in Overgrowth Syndromes in Adults and Children) trial of its oral, selective pan-AKT inhibitor, miransertib, for the treatment of Proteus syndrome (PS) and PIK3CA-related Overgrowth Spectrum disorders (PROS).

Key Points: 
  • ArQule, Inc. (Nasdaq: ARQL), today announced that the first patient was dosed in the registrational MOSAIC (Miransertib in Overgrowth Syndromes in Adults and Children) trial of its oral, selective pan-AKT inhibitor, miransertib, for the treatment of Proteus syndrome (PS) and PIK3CA-related Overgrowth Spectrum disorders (PROS).
  • We are pleased that the FDA has granted miransertib Fast Track Designation for PROS and Rare Pediatric Disease Designation for Proteus syndrome.
  • Proteus syndrome is an ultra-rare condition characterized by the aberrant overgrowth of multiple tissues of the body.
  • This press release contains forward-looking statements, including statements regarding the MOSAIC registrational study in Proteus syndrome and PROS.